Antitubercular, Antimalarial Activity and Molecular Docking Study of New Synthesized 7-Chloroquinoline Derivatives

References

• R. Mahajan, “Bedaquiline: First FDA-Approved Tuberculosis Drug in 40 Years,” International Journal of Applied and Basic Medical Research 3, no. 11 (2013): 1.
   PubMedGoogle Scholar
• World Healt Organization, “Global Tuerculosis Report” (WHO/CDC/TB/2019.15, Geneva: WHO, 2019).
   Google Scholar
• H. Yazisiz, D. Hircin Cenger, N. Uçarman, and S. Altin, “The Molecular Patterns of Resistance to Anti-Tuberculosis Drugs: An Analysis from Istanbul, Turkey,” Journal of Chemotherapy 32no. 2 (2020): 66–74. no.
   PubMed Web of Science ®Google Scholar
• World Health Organization, “World Malaria Report” (Geneva: WHO, 2019).
   Google Scholar
• A. Uddin, M. Chawla, I. Irfan, S. Mahajan, S. Singh, and M. Abid, “Medicinal Chemistry Updates on Quinoline- and Endoperoxide-Based Hybrids with Potent Antimalarial Activity,” RSC Medicinal Chemistry 12, no. 1 (2021): 24–42.
   PubMedGoogle Scholar
• J. A. Marinho, et al. “In Vitro and in Vivo Antiplasmodial Activity of Novel Quinoline Derivative Compounds by Molecular Hybridization,” European Journal of Medicinal Chemistry 215 (2021): 113271.
   PubMed Web of Science ®Google Scholar
• R. R. Soares, et al. “New Quinoline Derivatives Demonstrate a Promising Antimalarial Activity against Plasmodium falciparum in Vitro and Plasmodium berghei in Vivo,”Bioorganic & Medicinal Chemistry Letters 25, no. 11 (2015): 2308–13.
   PubMed Web of Science ®Google Scholar
• A. S. Ressurreição, et al. “Structural Optimization of Quinolon-4(1 H) -Imines as Dual-Stage Antimalarials: Toward Increased Potency and Metabolic Stability,” Journal of Medicinal Chemistry 56no. 19 (2013): 7679–90.
   PubMed Web of Science ®Google Scholar
• M. C. Joshi, and T. J. Egan, “Quinoline Containing Side-Chain Antimalarial Analogs: Recent Advances and Therapeutic Application,” Current Topics in Medicinal Chemistry 20, no. 8 (2020): 617–97.
   PubMed Web of Science ®Google Scholar
• F. A. Rojas Ruiz, et al. “Synthesis and Antimalarial Activity of New Heterocyclic Hybrids Based on Chloroquine and Thiazolidinone Scaffolds,” Bioorganic & Medicinal Chemistry 19, no. 15 (2011): 4562–73.
   PubMed Web of Science ®Google Scholar
• N. Yamasaki, et al. “A Concise Total Synthesis of Dehydroantofine and Its Antimalarial Activity against Chloroquine Resistant Plasmodium falciparum,” Chemistry–A European Journal 27, no. 17 (2021): 5555–63.
   PubMed Web of Science ®Google Scholar
• M. B. Rahul Reddy, S. K. Krishnasamy, and M. K. Kathiravan, “Identification of Novel Scaffold Using Ligand and Structure Based Approach Targeting Shikimate Kinase,” Bioorganic Chemistry 102 (2020): 104083.
   PubMed Web of Science ®Google Scholar
• B. Blanco, et al. “Mycobacterium tuberculosis Shikimate Kinase Inhibitors: Design and Simulation Studies of the Catalytic Turnover,” Journal of the American Chemical Society 135, no. 33 (2013): 12366–76.
   PubMed Web of Science ®Google Scholar
• S. Gordon, J. Simithy, D. C. Goodwin, and A. I. Calderón, “Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials,” Perspectives in Medicinal Chemistry 7 (2015): PMC.S13212. PMC.S13212,
   Web of Science ®Google Scholar
• J. Raman, C. S. Ashok, S. I. N. Subbayya, R. P. Anand, S. T. Selvi, and H. Balaram, “Plasmodium falciparum Hypoxanthine Guanine Phosphoribosyltransferase: Stability Studies on the Product-Activated Enzyme,” Federation of European Biochemical Societies 272, no. 8 (2005): 1900–11.
   PubMed Web of Science ®Google Scholar
• H. H. Jardosh, and M. P. Patel, “Design and Synthesis of Biquinolone–Isoniazid Hybrids as a New Class of Antitubercular and Antimicrobial Agents,” European Journal of Medicinal Chemistry 65, (2013): 348–59.
   PubMed Web of Science ®Google Scholar
• H. G. Kathrotiya, and M. P. Patel, “Synthesis and Identification of β-Aryloxyquinoline Based Diversely Fluorine Substituted N-Aryl Quinolone Derivatives as a New Class of Antimicrobial, Antituberculosis and Antioxidant Agents,” European Journal of Medicinal Chemistry 63, (2013): 675–84.
   PubMed Web of Science ®Google Scholar
• A. Rattan, Antimicrobials in Laboratory Medicine (New Delhi: Churchill BI, Livingstone, 85, 2000), 85–105.
   Google Scholar
• C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings 1PII of Original Article,” Advanced Drug Delivery Reviews 46, no. 1–3 (2001): 3–26.
   PubMed Web of Science ®Google Scholar
• Bratislava University, Molinspiration Cheminformatics (Nova ulica SK-900 26, Slovensky: Grob Slovak Republic, 1986).
   Google Scholar
• H. Pajouhesh, and G. R. Lenz, “Medicinal Chemical Properties of Successful Central Nervous System Drugs,” Neurotherapeutics 2, no. 4 (2005): 541–53.
   Google Scholar
• S. A. Hitchcock, and L. D. Pennington, “Structure − Brain Exposure Relationships,” Journal of Medicinal Chemistry 49, no. 26 (2006): 7559–83. 10.1021/jm060642i.
   PubMed Web of Science ®Google Scholar
• Ruben Abagyan, Max Totrov, and Eugene Raush, Molsoft L.L.C (San Diego CA: Molsoft L.L.C., 1994).
   Google Scholar